Lista de obras - M Beksac - Dominio Público Uruguay

A Case of Superwarfarin Poisoning Due to Repetitive Occupational Dermal Rodenticide Exposure in a Worker.

artículo científico publicado en 2016

A Novel Hypothesis: Certain KIR/Cognate Ligand Containing Genotypes Differ in Frequency Among Patients With Myeloma and Have an Effect on Age of Disease Onset

artículo científico publicado en 2023

Allogeneic Transplantation in Chronic Myeloid Leukemia and the Effect of Tyrosine Kinase Inhibitors on Survival: A Quasi-Experimental Study

artículo científico publicado en 2016

Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Marrow Transplantation (EBMT)

artículo científico publicado en 2020

Autologous Platelet Collection and Storage to Support Thrombocytopenia in a Leukemia Patient with Platelet Alloimmunization Undergoing Chemotherapy

artículo científico publicado en 2003

Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group

artículo científico publicado en 2021

Bone marrow microvessel density (MVD) in adult acute myeloid leukemia (AML): therapy induced changes and effects on survival

artículo científico publicado en 2004

Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study

scientific article published on 05 February 2014

Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients

artículo científico publicado en 2011

Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.

artículo científico publicado en 2016

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

artículo científico publicado en 2011

Current multiple myeloma treatment strategies with novel agents: a European perspective

scientific article published on 19 January 2010

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

artículo científico publicado en 2016

Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, Nordic and Turkish myeloma study groups.

artículo científico publicado en 2015

Editorial: "How to Improve Cord Blood Transplantation: By Enhancing Cell Counts or Engraftment?".

artículo científico publicado en 2016

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

artículo científico publicado en 2015

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth

artículo científico publicado en 2017

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

artículo científico publicado en 2020

European Myeloma Network guidelines for the management of multiple myeloma-related complications

artículo científico publicado en 2015

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

artículo científico publicado en 2014

Expression of IFITM1 in chronic myeloid leukemia patients.

artículo científico publicado en 2005

Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease

artículo científico publicado en 2004

Fetal Cell Microchimerism; Normal and Immunocompromised Gestations in Mice

scientific article published on 22 August 2019

Flow cytometric evaluation of cell cycle regulators (cyclins and cyclin-dependent kinase inhibitors) expressed on bone marrow cells in patients with chronic myeloid leukemia and multiple myeloma

artículo científico publicado en 2011

HLA polymorphism and risk of multiple myeloma

artículo científico publicado en 2016

Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or Bortezomib

artículo científico publicado en 2019

High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial

artículo científico publicado en 2013

How to Improve Cord Blood Engraftment?

artículo científico publicado en 2016

IMWG consensus on maintenance therapy in multiple myeloma

artículo científico publicado en 2012

Impact of "Killer Immunoglobulin-Like Receptor /Ligand" Genotypes on Outcome following Surgery among Patients with Colorectal Cancer: Activating KIRs Are Associated with Long-Term Disease Free Survival

artículo científico publicado en 2015

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

artículo científico publicado en 2014

Is There Any Reason to Prefer Cord Blood Instead of Adult Donors for Hematopoietic Stem Cell Transplants?

artículo científico publicado en 2015

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

artículo científico publicado en 2019

Multiple myeloma treatment strategies with novel agents in 2011: a European perspective

scientific article published on 26 March 2011

Myeloma as a Second Malignancy following AML: Is a Second Allo Equivalent to Auto?

artículo científico publicado en 2012

Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group

artículo científico publicado en 2008

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

artículo científico publicado en 2017

Our Treatment Approach to Hairy Cell Leukemia

artículo científico publicado en 2020

Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial

artículo científico publicado en 2016

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

artículo científico publicado en 2015

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

artículo científico publicado en 2014

Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial.

artículo científico publicado en 2017

Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma

artículo científico

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).

artículo científico publicado en 2011

Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation

artículo científico publicado en 2014

Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.

artículo científico publicado en 2016

Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma.

artículo científico publicado en 2006

Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma

artículo científico publicado en 2013

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

scientific article published on 13 May 2019

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

artículo científico publicado en 2018

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

artículo científico publicado en 2020

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

scientific article published on 11 February 2008

Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma

artículo científico publicado en 2014

Role of killer immunoglobulin-like receptor and ligand matching in donor selection

artículo científico publicado en 2012

Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials

artículo científico publicado en 2012

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials

artículo científico publicado en 2011

The evolving treatment paradigm of multiple myeloma: From past to present and future

artículo científico publicado en 2008

The shaping of modern human immune systems by multiregional admixture with archaic humans

artículo científico publicado en 2011

Vitiligo after hematopoietic cell transplantation: six cases and review of the literature

artículo científico publicado en 2008

Lista de obras de M Beksac

A Case of Superwarfarin Poisoning Due to Repetitive Occupational Dermal Rodenticide Exposure in a Worker.

A Novel Hypothesis: Certain KIR/Cognate Ligand Containing Genotypes Differ in Frequency Among Patients With Myeloma and Have an Effect on Age of Disease Onset

Allogeneic Transplantation in Chronic Myeloid Leukemia and the Effect of Tyrosine Kinase Inhibitors on Survival: A Quasi-Experimental Study

Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Marrow Transplantation (EBMT)

Autologous Platelet Collection and Storage to Support Thrombocytopenia in a Leukemia Patient with Platelet Alloimmunization Undergoing Chemotherapy

Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group

Bone marrow microvessel density (MVD) in adult acute myeloid leukemia (AML): therapy induced changes and effects on survival

Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study

Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients

Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

Current multiple myeloma treatment strategies with novel agents: a European perspective

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, Nordic and Turkish myeloma study groups.

Editorial: "How to Improve Cord Blood Transplantation: By Enhancing Cell Counts or Engraftment?".

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

European Myeloma Network guidelines for the management of multiple myeloma-related complications

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

Expression of IFITM1 in chronic myeloid leukemia patients.

Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease

Fetal Cell Microchimerism; Normal and Immunocompromised Gestations in Mice

Flow cytometric evaluation of cell cycle regulators (cyclins and cyclin-dependent kinase inhibitors) expressed on bone marrow cells in patients with chronic myeloid leukemia and multiple myeloma

HLA polymorphism and risk of multiple myeloma

Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or Bortezomib

High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial

How to Improve Cord Blood Engraftment?

IMWG consensus on maintenance therapy in multiple myeloma

Impact of "Killer Immunoglobulin-Like Receptor /Ligand" Genotypes on Outcome following Surgery among Patients with Colorectal Cancer: Activating KIRs Are Associated with Long-Term Disease Free Survival

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

Is There Any Reason to Prefer Cord Blood Instead of Adult Donors for Hematopoietic Stem Cell Transplants?

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Multiple myeloma treatment strategies with novel agents in 2011: a European perspective

Myeloma as a Second Malignancy following AML: Is a Second Allo Equivalent to Auto?

Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

Our Treatment Approach to Hairy Cell Leukemia

Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial.

Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).

Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation

Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.

Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma.

Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma

Role of killer immunoglobulin-like receptor and ligand matching in donor selection

Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials

The evolving treatment paradigm of multiple myeloma: From past to present and future

The shaping of modern human immune systems by multiregional admixture with archaic humans

Vitiligo after hematopoietic cell transplantation: six cases and review of the literature